399 related articles for article (PubMed ID: 30134351)
1. Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy.
Strauss KA; Carson VJ; Brigatti KW; Young M; Robinson DL; Hendrickson C; Fox MD; Reed RM; Puffenberger EG; Mackenzie W; Miller F
J Pediatr Orthop; 2018; 38(10):e610-e617. PubMed ID: 30134351
[TBL] [Abstract][Full Text] [Related]
2. Nusinersen Administration Via an Intrathecal Port in a 16-Year-Old Spinal Muscular Atrophy Patient with Profound Scoliosis.
Flotats-Bastardas M; Linsler S; Zemlin M; Meyer S
Pediatr Neurosurg; 2020; 55(1):54-57. PubMed ID: 31722365
[TBL] [Abstract][Full Text] [Related]
3. Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy.
Carson VJ; Young M; Brigatti KW; Robinson DL; Reed RM; Sohn J; Petrillo M; Farwell W; Miller F; Strauss KA
Muscle Nerve; 2022 Jan; 65(1):51-59. PubMed ID: 34606118
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Experience with Nusinersen Application via an Intrathecal Port and Catheter System in Spinal Muscular Atrophy.
Flotats-Bastardas M; Hahn A; Schwartz O; Linsler S; Meyer S; Kolodziej M; Koehler C
Neuropediatrics; 2020 Dec; 51(6):401-406. PubMed ID: 33091940
[TBL] [Abstract][Full Text] [Related]
6. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
Chiriboga CA; Swoboda KJ; Darras BT; Iannaccone ST; Montes J; De Vivo DC; Norris DA; Bennett CF; Bishop KM
Neurology; 2016 Mar; 86(10):890-7. PubMed ID: 26865511
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal catheter and port placement for nusinersen infusion in children with spinal muscular atrophy and spinal fusion.
Shashi KK; Stone SSD; Berde CB; Padua HM
Pediatr Radiol; 2021 Dec; 51(13):2588-2595. PubMed ID: 34254153
[TBL] [Abstract][Full Text] [Related]
8. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model.
MacCannell D; Berger Z; Kirschner J; Mercuri E; Farrar MA; Iannaccone ST; Kuntz NL; Finkel RS; Valente M; Muntoni F
CNS Drugs; 2022 Feb; 36(2):181-190. PubMed ID: 35080757
[TBL] [Abstract][Full Text] [Related]
9. Administration of nusinersen via paramedian approach for spinal muscular atrophy.
Iwayama H; Wakao N; Kurahashi H; Kubota N; Hattori A; Kumagai T; Okumura A
Brain Dev; 2021 Jan; 43(1):121-126. PubMed ID: 32773161
[TBL] [Abstract][Full Text] [Related]
10. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
[TBL] [Abstract][Full Text] [Related]
11. Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1.
Pechmann A; Langer T; Wider S; Kirschner J
Eur J Paediatr Neurol; 2018 Jan; 22(1):122-127. PubMed ID: 29208343
[TBL] [Abstract][Full Text] [Related]
12. Transforaminal intrathecal delivery of nusinersen for older children and adults with spinal muscular atrophy and complex spinal anatomy: an analysis of 200 consecutive injections.
Weaver JJ; Hallam DK; Chick JFB; Vaidya S; Shin DS; Natarajan N; Rad N; Reis J; Koo KSH; Shivaram GM; Thibodeau A; Apkon S; Monroe EJ
J Neurointerv Surg; 2021 Jan; 13(1):75-78. PubMed ID: 32471828
[TBL] [Abstract][Full Text] [Related]
13. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
14. Pediatric SMA patients with complex spinal anatomy: Implementation and evaluation of a decision-tree algorithm for administration of nusinersen.
Carrera-García L; Muchart J; Lazaro JJ; Expósito-Escudero J; Cuadras D; Medina J; Bosch de Basea M; Colomer J; Jimenez-Mallebrera C; Ortez C; Natera-de Benito D; Nascimento A
Eur J Paediatr Neurol; 2021 Mar; 31():92-101. PubMed ID: 33711792
[TBL] [Abstract][Full Text] [Related]
15. Nusinersen for the treatment of spinal muscular atrophy.
Chiriboga CA
Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
[TBL] [Abstract][Full Text] [Related]
16. Scoliosis and spinal muscular atrophy in the new world of medical therapy: providing lumbar access for intrathecal treatment in patients previously treated or undergoing spinal instrumentation and fusion.
Labianca L; Weinstein SL
J Pediatr Orthop B; 2019 Jul; 28(4):393-396. PubMed ID: 30932967
[TBL] [Abstract][Full Text] [Related]
17. Laboratory monitoring of nusinersen safety.
Goedeker NL; Gibbons JL; Varadhachary AS; Connolly AM; Zaidman CM
Muscle Nerve; 2021 Jun; 63(6):902-905. PubMed ID: 33675054
[TBL] [Abstract][Full Text] [Related]
18. Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safety.
Weaver JJ; Natarajan N; Shaw DWW; Apkon SD; Koo KSH; Shivaram GM; Monroe EJ
Pediatr Radiol; 2018 Mar; 48(3):392-397. PubMed ID: 29130140
[TBL] [Abstract][Full Text] [Related]
19. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
20. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Bishop KM; Foster R; Liu Y; Ramirez-Schrempp D; Schneider E; Bennett CF; Wong J; Farwell W
Lancet Child Adolesc Health; 2021 Jul; 5(7):491-500. PubMed ID: 34089650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
